Gilead Sciences received FDA approval and preferred status via NCC review for its drug Trodelvy.
1 report, 1 independent
Updated Jul 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Gilead Sciences received FDA approval and preferred status via NCC review for its drug Trodelvy.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
- FDA
Related events
- Gilead Sciences acquired Arcellx and presented priorities at a Wells Fargo conference, while also discussing submissions with the FDA and CDC.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- The FDA is reviewing a drug approval application for a condition involving the company GAD.
- GSK and EXEL are developing treatments for PBC, and the FDA granted accelerated approval to Gilead Sciences for related therapies.
- BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.